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1176 Abstracts April 2014for elective surgery. At 18 months, doxycycline did not decrease aneurysm
growth compared with the control group. In fact, there was a small increase
in aneurysm growth of 4.1 mm (95% conﬁdence interval [CI], 3.6-4.5 mm)
in the doxycycline group vs 3.3 mm (95% CI, 2.8-3.7 mm) in the control
group at 18 months. The difference in diameter growth was 0.8 mm
(95% CI, 0.1-1.4 mm; P ¼ .016). Twenty-one patients receiving doxycy-
cline and 22 receiving placebo had elective surgical repair. Kaplan-Meier es-
timates for elective surgical repair were 16.1% for those receiving
doxycycline and 16.5% receiving placebo; difference, 0.4% (95% CI,
9.3% to 8.5%; P ¼ .83). Time to aneurysm repair was also similar in the
groups (P ¼ .92).
Comment: One of the holy grails of vascular disease is a pill to prevent
development of AAAs in patients at risk or slow progression of the AAA in
those with small aneurysms. As such, the results of this study are disap-
pointing, because doxycycline has been considered the leading candidate
for medical management of aortic aneurysm disease. There is currently in
the United States a National Institute of Health-sponsored smaller trial of
doxycycline, using twice the dose of doxycycline used in the Dutch trial,
for management of small AAAs. The results of this study will not likely be
available for several years. Apparently, however, one needs to consider the
possibility that our current understanding of the biochemical mechanisms
of aneurysm formation may be insufﬁcient to develop a precisely targeted
pharmacologic intervention.
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed M, Burnside G, Eriksson N, and EU-PACT Group. N Engl J
Med 2013;369:2294-303
Conclusions: Pharmacogenetic-based dosing is associated with a
higher percentage of time in therapeutic international normalized ratio
(INR) range than standard dosing during initiation of warfarin therapy.
Summary: Warfarin has a wide variation of dosages needed to achieve
relatively narrow therapeutic indices. This variation can be due to insufﬁ-
cient or excessive anticoagulation. Polymorphisms in two genes, CYP2C9
(involved in the metabolism of the pharmacologically more potent S-enan-
tiomer of warfarin) and VKORC1 (involved in the vitamin K cycle), in com-
bination with age and body surface area, are known to account forw50% of
the variability in the individual daily dose requirements for warfarin (John-
son JA et al, Clin Pharmacol Ther 2011;90:625-9; and Yang J et al, Int J
Cardiol 2013;168:4234-43). Indeed, the U.S. Food and Drug Administra-
tion changed the drug label for warfarin to include the statement “The pa-
tient’s CYP2C9 and VKORC1 genotype information, when available, can
assist in selection of the starting dose for warfarin.” (Finkelman BS et al,
J Am CollCardiol 2011;57:612-8). However, lack of data from randomized
trials has led to the fact that genotyping before a prescription of warfarin is
not recommended in clinical practice guidelines (Holbrook A et al, Chest
2012;141(Suppl):e152-84S). There have been prospective studies and ran-
domized trials that failed to show genotyping improves anticoagulation con-
trol, but despite these, a recent study also showed that genotype-guided
dosing led to superior control of anticoagulation (Anderson JL et al, Circu-
lation 2012;125:1997-2005). In this study, the authors prospectively
compared the effect of genotype-guided dosing with that of standard dosing
on anticoagulation control in patients starting warfarin therapy. This was a
multicenter, randomized, control trial involving patients with atrial ﬁbrilla-
tion or venous thromboembolism. Genotyping for CYP2C9*2, CYP2C9*3,
and VKORC1 (e1639G/A) was performed using a point-of-care test. For
patients assigned to the genotype-guided group, warfarin doses were pre-
scribed according to pharmacogenetic-based algorithms for the ﬁrst 5
days. Patients in the standard-dosing group (controls) received a 3-day
loading-dose regimen. After the initiation period, treatment management
of all patients was according to routine clinical practice. The primary
outcome measure was the percentage of time in the therapeutic range,
with 2.0 to 3.0 the goal for the INR during the ﬁrst 12 weeks after initiation
of warfarin therapy. The study recruited 455 patients, and 227 were
randomly assigned to the genotype-guided group and 228 to the control
group. The mean percentage of time in the therapeutic range was 67.4%
in the genotype-guided group compared with 60.3% in the control group
(adjusted difference, 7.0 percentage points; 95% conﬁdence interval, 3.3-
10.6; P < .001). Signiﬁcantly fewer incidences of excessive anticoagulation
(INR $4.0) occurred in the genotype-guided group. Median time to reach
therapeutic INR was 21 days in the genotype-guided group compared with
29 days in the control group (P < .001).
Comment: The trial has a number of weaknesses, including the fact
that the majority of patients are of European ethnic background and the re-
sults can therefore perhaps not be generalized to other ethnic groups. Butmost importantly, the outcome measure was time in so-called therapeutic
range rather than clinical outcome measures of bleeding and thrombosis.
Whether genotype-guided dosing of warfarin therapy can lead to improved
clinical outcomes in a setting outside of a clinical trial remains to be deter-
mined. Indeed, the future role of warfarin anticoagulation in the era where
not all anticoagulation agents will not require monitoring will remain to be
determined. It may be, in the future, that many of the patients included in
this trial will not even be considered for warfarin anticoagulation but will be
preferentially treated by the new oral activated 10a inhibitors.
A Risk Prediction Model for Determining Appropriateness of CEA in
Patients With Asymptomatic Carotid Artery Stenosis
Conrad MF, Kang J, Mukhopadhyay S, et al. Ann Surg 2013;258:534-40.
Conclusions: A scoring system based on the probability of long-term
survival can be used to determine patients most likely to beneﬁt from carotid
endarterectomy (CEA).
Summary: There is considerable controversy about which patients
with asymptomatic carotid stenosis, even high-grade asymptomatic carotid
stenosis, are most likely to beneﬁt from a prophylactic CEA. Indeed, there
are those who believe that asymptomatic carotid stenosis may be best
treated with carotid artery stenting and those who also contend that with
modern medical therapy, asymptomatic carotid stenosis may be best treated
with medical therapy alone. Although it seems intuitive that life expectancy
should be considered in the decision to perform prophylactic CEA, there are
also a number of other variables, such as plaque morphology, degree of ipsi-
lateral carotid stenosis, degree of contralateral carotid stenosis, presence and
number of asymptomatic cerebral infarcts, and patient willingness and ability
to adhere to maximum medical management of atherosclerotic risk factors,
that all can play a role in the decision to perform prophylactic CEA. Indeed,
the authors point out that a recent document from the Society for Vascular
Surgery reported to guide clinical research goals for the next 10 years indi-
cated that optimal management of asymptomatic carotid stenosis was the
top priority (Kraiss LW et al, J Vasc Surg 2013;57:493-500). The goal of
this study was for the authors to create a scoring system to predict 5-year
survival after CEA that would be useful in selecting, or at least helping to
select, patients with asymptomatic carotid stenosis for prophylactic CEA.
The data were based on patients who underwent CEA for severe asymptom-
atic carotid stenosis from 1989 to 2005 at the authors’ institution. Long-
term survival of these patients was determined by a review of hospital
records and the Social Security Death Index. All patients had a potential
for at least 5 years of follow-up. A logistic regression of predictors of survival
at 5 years was performed, and the odds ratios associated with the analysis of
signiﬁcant comorbidities were used to create a scoring system to predict sur-
vival. The scoring system was then validated within the cohort using the
Hosmer-Lemeshow test and a derivation/validation receiver operating
characteristic (ROC) curve. There were 2004 CEA procedures performed
in 1791 patients. The average follow-up was 130 6 49 months. Eighty-
four percent of the patients were hypertensive, 56% had coronary artery dis-
ease, 24% diabetes, and 71% were taking statins. The 30-day stroke rate was
1.1%, and the mortality rate was 0.7%. Actual 5-year survival was 73%.
Predictors of death by logistic regression analysis were age by decade
(odds ratio [OR], 1.8; P < .0001), coronary artery disease (OR, 1.5;
P ¼ .0007), chronic obstructive pulmonary disease (OR, 2.5; P < .0001),
diabetes (OR, 1.7; P < .0001), neck radiation (OR, 2.6; P ¼ .005),
no statin (OR, 2.1; P < .0001), and creatinine >1.5 mg/dL (OR, 2.6;
P < .0001). The variables were then assigned a hierarchal point scoring sys-
tem in accordance with the OR value. The 5-year survival based on the
scoring system was 0 to 5 points, 92.5%, 6 to 8 points, 83.6%; 9 to 11
points, 63.7%; 12 to 14 points, 46.5%; and >15 points, 33.8%. The
Hosmer-Lemeshow test validated the scoring system (P ¼ .26), and there
was no difference in the ROC curves (C statistic, 0.74 vs 0.73).
Comment: Like many surgical series, the data here are highly preju-
diced in that they were derived from patients who actually had a CEA
and were from only a single institution in the Northeast. The potential
for unrecognized confounding variables possibly inﬂuencing the logistic
regression analysis is therefore high. The authors’ data suggest they may
be fairly conservative in selecting their patients, because the highest risk
score for 5-year survival among their patients was 18, with a maximum
possible score of 35. Perhaps the most salient feature of this report is to
demonstrate to our medical colleagues that surgeons really do try to exercise
judgment in their selection of patients for CEA. Selection of patients for
CEA with reasonable life spans is certainly part of that judgment, but
perhaps selection of patients at most risk for disabling stroke or stroke-
related death is also part of that judgment.
